Real-World Efficacy and Safety of Nadofaragene Firadenovec in Non–Muscle-Invasive Bladder Cancer

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.

The intravesical therapy nadofaragene firadenovec yielded a 79% 3-month CR rate in patients with CIS with or without papillary disease in a real-world study.